Unicycive Therapeutics In... (UNCY)
Unicycive Therapeutics Statistics
Share Statistics
Unicycive Therapeutics has 119.7M shares outstanding. The number of shares has increased by 176% in one year.
| Shares Outstanding | 119.7M |
| Shares Change (YoY) | 176% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 69.36% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,649 |
| FTD / Avg. Volume | 0.82% |
Short Selling Information
The latest short interest is 1.04M, so 1% of the outstanding shares have been sold short.
| Short Interest | 1.04M |
| Short % of Shares Out | 1% |
| Short % of Float | 1.08% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -14.07 and the forward PE ratio is 0.66. Unicycive Therapeutics's PEG ratio is 0.15.
| PE Ratio | -14.07 |
| Forward PE | 0.66 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 71.59 |
| P/FCF Ratio | -18.57 |
| PEG Ratio | 0.15 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Unicycive Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.28 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 452.35 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,719,272.73 |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -41.96% in the last 52 weeks. The beta is 2.15, so Unicycive Therapeutics's price volatility has been higher than the market average.
| Beta | 2.15 |
| 52-Week Price Change | -41.96% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.53 |
| Relative Strength Index (RSI) | 60.79 |
| Average Volume (20 Days) | 929,242 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.12M |
| Net Income | -37.82M |
| EBITDA | -32.12M |
| EBIT | -37.9M |
| Earnings Per Share (EPS) | -0.06 |
Balance Sheet
The company has 26.14M in cash and 681K in debt, giving a net cash position of 25.46M.
| Cash & Cash Equivalents | 26.14M |
| Total Debt | 681K |
| Net Cash | 25.46M |
| Retained Earnings | -101.27M |
| Total Assets | 31.67M |
| Working Capital | 6.83M |
Cash Flow
In the last 12 months, operating cash flow was -28.57M and capital expenditures -72K, giving a free cash flow of -28.65M.
| Operating Cash Flow | -28.57M |
| Capital Expenditures | -72K |
| Free Cash Flow | -28.65M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
UNCY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for UNCY is $6, which is 823.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 823.1% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -7.93 |
| Piotroski F-Score | 2 |